Health Care & Pharma

Regado Bioscience announces closing of public offering of common stock

April 16, 2014 at 1:39 PM

Basking Ridge-based Regado Biosciences Inc. announced Wednesday the closing of its previously announced public offering.

According to the announcement, the gross proceeds to Regado from its sale of 10 million shares of its stock at a $6.00 price per share were approximately $60 million.

Regado expects to use the money to fund further clinical development of its lead product, REG1, and for working capital and other general corporate purposes, the announcement said.

Jefferies LLC, Deutsche Bank Securities and Cowen and Company LLC acted as joint bookrunning managers for the offering.

ALSO ON NJBIZ:

Horizon making major change in coverage

Christie's desire to eliminate realty transfer fees is applauded by industry

New Jersey ranks poorly in Rich States, Poor States report

Also Popular on NJBIZ

• Flight Center Travel Group opens new office, reaffirms commitment to N.J. • Princeton professor overcomes challenges facing women in science to earn N.J. Chamber honor • South Jersey logistics complex getting another tenant • As women gain control of wealth, it is vital for them to know how to handle it, Carol Stillwell says

Comments

Also on NJBIZ.com

8 N.J. companies on Working Mother magazine's 100 Best Companies for working mothers

Flight Center Travel Group opens new office, reaffirms commitment to N.J.

Breaking Glass: As women gain control of wealth, it is vital for them to know how to handle it, Carol Stillwell says

NJBIZ